Affiliation:
1. Department of Biostatistics Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA
2. Division of Quantitative Sciences, Department of Oncology Johns Hopkins School of Medicine Baltimore Maryland USA
Abstract
AbstractCompeting risks data are commonly encountered in randomized clinical trials or observational studies. Ignoring competing risks in survival analysis leads to biased risk estimates and improper conclusions. Often, one of the competing events is of primary interest and the rest competing events are handled as nuisances. These approaches can be inadequate when multiple competing events have important clinical interpretations and thus of equal interest. For example, in COVID‐19 in‐patient treatment trials, the outcomes of COVID‐19 related hospitalization are either death or discharge from hospital, which have completely different clinical implications and are of equal interest, especially during the pandemic. In this paper we develop nonparametric estimation and simultaneous inferential methods for multiple cumulative incidence functions (CIFs) and corresponding restricted mean times. Based on Monte Carlo simulations and a data analysis of COVID‐19 in‐patient treatment clinical trial, we demonstrate that the proposed method provides global insights of the treatment effects across multiple endpoints.
Funder
National Institutes of Health
Subject
Statistics and Probability,Epidemiology